本周医药板块表现弱于整体市场，医药商业降幅居前。本周全部 A 股下 跌 0.98%（总市值加权平均），沪深 300 上涨 0.08%，中小板指下跌 3.78%，创业板指下跌 0.09%，生物医药板块整体下跌 3.31%，生物医 药板块表现弱于整体市场。分子板块来看，化学制药下跌 3.20%，生物 制品下跌 2.50%，医疗服务下跌 4.15%，医疗器械下跌 3.86%，医药商 业下跌 4.49%，中药下跌 1.94%。医药生物市盈率（TTM）37.27x，处 于近 5 年历史估值的 80.47%分位数。 精锋医疗为领先的手术机器人公司。精锋医疗成立于 2017 年，是中国 首家、全球第二家同时取得多孔腔镜、单孔腔镜及自然腔道三类手术机 器人注册审批的领先企业，2024 年斩获国内手术机器人制造商销量第 一，2026 年 1 月于香港联交所挂牌上市。公司核心管理层具备深厚的 行业经验与国际背景，全球专利布局超 734 项，技术实力雄厚。 精锋医疗构建了覆盖多科室的丰富管线。多孔系列 MP1000 及升级款 已获批多专科应用并实现商业化放量，单孔系列 SP1000 为国内首个 覆盖三大外科的国产单孔机器人，支气管 ...

Core Viewpoint - The collaboration between Sichuan Huaxi Hospital and Tibet Maternal and Child Hospital successfully completed the world's first remote single-arm single-port robotic surgery, highlighting the growing application of surgical robots in the medical field and the potential to bridge healthcare disparities across regions [1][7]. Group 1: Advantages of Surgical Robots - Surgical robots serve as "assisted driving systems" on the operating table, enabling precise and complex surgical operations [1]. - They significantly enhance surgical precision and stability, reducing human error and risks associated with surgeries [3]. - The use of surgical robots can drastically reduce operation time; for instance, the SEEG electrode implantation procedure can be completed in 40-50 minutes compared to 120-180 minutes using traditional methods [5]. Group 2: Current Market Status - The global surgical robot market is projected to grow from approximately $11.1 billion in 2024 to $23.7 billion by 2029, with a compound annual growth rate (CAGR) of 16.5% [8]. - Intuitive Surgical's da Vinci surgical robot holds about 60% of the global market share, indicating a dominant position in the industry [8][11]. Group 3: Domestic Development and Challenges - China's surgical robot industry has transitioned from reliance on imports to independent research and development, achieving breakthroughs in various surgical fields [11][13]. - Despite advancements, challenges remain, including reliance on imported core components and difficulties in market promotion, which hinder the widespread adoption of domestic surgical robots [13][15]. - The price of domestic laparoscopic surgical robots is significantly lower, ranging from 3-4 million RMB, compared to 8-12 million RMB for imported models [11]. Group 4: Technological Innovations and Future Prospects - The emergence of technologies like DeepSeek represents a pivotal moment for China's surgical robot industry, indicating a shift towards greater innovation and capability [16][18]. - The integration of AI and 5G technology is enhancing the functionality of surgical robots, allowing for remote surgeries and improved operational efficiency [27][29]. - The domestic market is seeing an increase in the approval of surgical robots, with 64% of devices being domestically produced, marking a significant improvement over the past four years [29].

Group 1 - The Hong Kong stock market welcomed three "hard technology" IPOs on January 8, with all three stocks experiencing gains [1] - Among them, Precision Medical showed the most impressive performance, rising over 26% [2] - Precision Medical raised HKD 1.2 billion (approximately USD 154 million) in its IPO, with a share price of HKD 43.24 and a subscription ratio of 1,091.94 times for the public offering [4] Group 2 - Tian Shu Zhi Xin also performed strongly, with a stock increase of nearly 15% [4] - Tian Shu Zhi Xin is recognized as a leading GPU chip and computing system provider in China, being the first to achieve mass production of inference and training general-purpose GPU chips [6] - The company has also utilized advanced 7nm process technology to reach these milestones [6] Group 3 - Zhi Pu experienced a fluctuation with a rise of over 5%, despite previously breaking its initial offering price [8] - The IPO plan for Zhi Pu includes issuing 37.42 million H-shares at a price of HKD 116.20 per share, aiming to raise approximately HKD 4.348 billion, with an expected market capitalization exceeding HKD 51.1 billion post-listing [9] - The public offering portion of Zhi Pu's IPO received approximately 1,164 times oversubscription [9]

智通财经获悉，12月19日，中国证监会公布境外发行上市备案补充材料要求公示(2025年12月15日— 2025年12月19日)。证监会要求精锋医疗说明2022年7月公司赴港上市申请获我会核准后，在核准批复有 效内未能在港上市的原因，是否构成本次赴港上市的实质障碍。据港交所2023年1月11日披露，精锋医 疗递表港交所，摩根士丹利、中金公司和花旗担任联席保荐人。 同时，证监会要求精锋医疗补充说明以下事项，请律师核查并出具明确的法律意见： 说明公司回购精诚瑞锋(深圳)科技合伙企业(有限合伙)合伙人王希文所持股权激励份额的进展，并就员 工持股计划是否合法合规、是否存在利益输送出具明确结论性意见。说明本次拟参与"全流通"股东所持 股份是否存在被质押、冻结或其他权利瑕疵的情形。 据此前招股书，精锋医疗致力于设计、开发及制造手术机器人。精锋®多孔腔镜手术机器人MP1000为 公司建议核心产品，而精锋®单孔腔镜手术机器人SP1000为关键在研产品。根据弗若斯特沙利文的资 料，公司是中国首家已完成多孔及单孔腔镜手术机器人关键性临床试验的公司。MP1000及SP1000均已 具备通过绿色通道进行国家药监局有关创新医疗器械的快速 ...

同时，证监会要求精锋医疗补充说明以下事项，请律师核查并出具明确的法律意见： 据此前招股书，精锋医疗致力于设计、开发及制造手术机器人。精锋®多孔腔镜手术机器人MP1000为 公司建议核心产品，而精锋®单孔腔镜手术机器人SP1000为关键在研产品。根据弗若斯特沙利文的资 料，公司是中国首家已完成多孔及单孔腔镜手术机器人关键性临床试验的公司。MP1000及SP1000均已 具备通过绿色通道进行国家药监局有关创新医疗器械的快速审查资格。公司于2022年12月获得国家药监 局对MP1000用于泌尿外科手术的注册批准。 2025年1月健稜投资受让嘉兴繸子马太股权投资合伙企业(有限合伙)所持发行人股份，2025年6月社保基 金中关村自主创新投资基金(北京)合伙企业(有限合伙)、苏州君联相道股权投资合伙企业(有限合伙)受让 协力创峰(深圳)所持公司股份，请按照最近12个月内新增股东核查要求对上述主体进行补充核查。 说明在未行使超额配售权和全额行使超额配售权下，发行股数占发行后总股本比例，预计募集资金量， 以及本次发行前后股权结构对比情况。说明公司历史沿革中是否存在股权代持，并就公司设立及历次股 权变动是否合法合规出具结论性意 ...